Results of second salvage therapy in 673 adults with acute myelogenous leukemia treated at a single institution since 2000.
Hagop M KantarjianCourtney D Di NardoGraciela M Nogueras-GonzalezTapan Mahendra KadiaElias J JabbourCarlos E Bueso-RamosSusan M O'BrienMarina KonoplevaNitin B JainNaval G DaverElizabeth J ShpallRichard E ChamplinAron SimkinsGuillermo Garcia-ManeroMichael J KeatingXuelin HuangJorge E CortesSherry A PierceFarhad RavandiEmil J FreireichPublished in: Cancer (2018)
This large-scale analysis establishes the modern historic results of second salvage therapy in AML and validates the prognostic models associated with outcome. These data could be used to analyze the differential benefits of current or future investigational strategies under evaluation in this setting and for the purpose of potential approval of new agents in the United States and the world. Cancer 2018;124:2534-40. © 2018 American Cancer Society.
Keyphrases
- squamous cell
- acute myeloid leukemia
- stem cells
- squamous cell carcinoma
- randomized controlled trial
- current status
- big data
- allogeneic hematopoietic stem cell transplantation
- acute lymphoblastic leukemia
- cell therapy
- artificial intelligence
- human health
- hepatitis b virus
- lymph node metastasis
- study protocol
- papillary thyroid
- phase iii